Earnings call transcript: Stoke Therapeutics beats Q2 2025 expectations

Stoke Therapeutics (STOK) significantly surpassed Q2 2025 expectations, reporting a narrower loss of -$0.40 EPS and revenue of $13.8 million, well above forecasts. This strong financial performance, bolstered by a cash runway extending to mid-2028, led to a 2.81% stock increase and further aftermarket gains. Key operational highlights include positive 3-year open-label extension data for lead Dravet syndrome candidate Zorivanersen, demonstrating durable seizure reductions and cognitive/behavioral improvements, alongside the initiation of its Phase III EMPEROR study. Furthermore, STOK expanded its pipeline by commencing a Phase I study for STK002 in autosomal dominant optic atrophy, underscoring its platform's potential and strategic growth.

Analysis

Stoke Therapeutics (STOK) reported a robust Q2 2025, significantly exceeding analyst forecasts with revenue of $13.8 million against an expected $9.39 million and a narrower loss per share of -$0.40 versus a -$0.50 consensus. This financial outperformance, driven by collaborations with ACADIA and Biogen, is supported by a formidable balance sheet, featuring a cash position of $355 million that provides a runway through mid-2028. This funding timeline is critical as it extends beyond the anticipated 2027 data readout for its pivotal Phase III EMPEROR study. Operationally, the company's lead asset, Zorivanersen for Dravet syndrome, demonstrated compelling three-year open-label extension data, showing not only durable seizure reductions but also continuous improvements in cognition and behavior, reinforcing its potential as a disease-modifying therapy. The initiation of the Phase III study, combined with an existing Breakthrough Therapy Designation, sets the stage for a key discussion with the FDA in the second half of this year regarding a potential accelerated approval pathway. Furthermore, the company has expanded its clinical pipeline by initiating a Phase I study for STK-002 in autosomal dominant optic atrophy (ADOA), signaling the broader potential of its antisense oligonucleotide platform.

Key Decisions for Investors

• Investors should evaluate Stoke Therapeutics based on the significantly de-risked clinical profile of its lead asset, Zorivanersen, whose positive three-year data reinforces its potential as a first-in-class, disease-modifying therapy for Dravet syndrome.
• A key near-term catalyst to monitor is the outcome of discussions with the FDA in the second half of the year, as any indication of an accelerated approval pathway could materially shorten the timeline to commercialization and unlock significant value.
• The company's strong cash position through mid-2028 mitigates financing risk through its key clinical milestones, providing a defensive characteristic rare among late-stage biotech firms.
• While Zorivanersen remains the primary value driver, the initiation of the STK-002 trial in ADOA provides early validation of the platform's broader applicability and should be factored into long-term growth models.